



Title	Update in management of hepatocellular carcinoma in Eastern population
Author(s)	Chu, KK; Cheung, TT
Citation	World Journal of Hepatology, 2015, v. 7 n. 11, p. 1562-1571
Issued Date	2015
URL	http://hdl.handle.net/10722/217271
Rights	Creative Commons: Attribution 3.0 Hong Kong License

Update in management of hepatocellular carcinoma in Eastern population

Kevin Ka Wan Chu, Tan To Cheung

Kevin Ka Wan Chu, Tan To Cheung, Department of Surgery, the University of Hong Kong, Hong Kong, China

Author contributions: Chu KKW and Cheung TT prepared and wrote the manuscript.

Conflict-of-interest: There is no conflict of interest.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Correspondence to: Tan To Cheung, MBBS (HK), FHKAM (Surgery), FCSHK, FRCS (Edin), Department of Surgery, the University of Hong Kong, 102 Pokfulam Road, Hong Kong, China. tantocheung@hotmail.com
Telephone: +852-22553025
Fax: +852-28165284

Received: November 27, 2014

Peer-review started: November 29, 2014

First decision: January 20, 2015

Revised: February 10, 2015

Accepted: April 10, 2015

Article in press: April 14, 2015

Published online: June 18, 2015

Abstract

Hepatocellular carcinoma (HCC) is one of the commonest malignant tumours in the East. Although the management of HCC in the West is mainly based on the Barcelona Clinic for Liver Cancer staging, it is considered too conservative by Asian countries where the number of HCC patients is huge. Scientific and clinical advances were made in aspects of diagnosis, staging, and treatment of HCC. HCC is well known to be

associated with cirrhosis and the treatment of HCC must take into account the presence and stage of chronic liver disease. The major treatment modalities of HCC include: (1) surgical resection; (2) liver transplantation; (3) local ablation therapy; (4) transarterial locoregional treatment; and (5) systemic treatment. Among these, resection, liver transplantation and ablation therapy for small HCC are considered as curative treatment. Portal vein embolisation and the associating liver partition with portal vein ligation for staged hepatectomy may reduce dropout in patients with marginally resectable disease but the midterm and long-term results are still to be confirmed. Patient selection for the best treatment modality is the key to success of treatment of HCC. The purpose of current review is to provide a description of the current advances in diagnosis, staging, pre-operative liver function assessment and treatment options for patients with HCC in the east.

Key words: Hepatocellular carcinoma; Liver cirrhosis; Treatment; Management; Evidence; Survival; Update

© **The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Management of hepatocellular carcinoma (HCC) has changed significantly over the past several decades. However, the management of patients has yet to be standardized. As a result of high prevalence of hepatitis B infection in Asia, the experience of the East helped to develop a more aggressive management algorithm. There has been a lot of advancement in terms of diagnosis, management algorithm, staging and treatment methods. This paper will give an update on the management of HCC in the eastern population.

Chu KKW, Cheung TT. Update in management of hepatocellular carcinoma in Eastern population. *World J Hepatol* 2015; 7(11): 1562-1571 Available from: URL: <http://www.wjgnet.com/1948-5182/full/v7/i11/1562.htm> DOI: <http://dx.doi.org/10.4254/wjh.v7.i11.1562>

INTRODUCTION

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer-related deaths worldwide^[1]. Because of the high prevalence of hepatitis B virus infection^[2], countries in Eastern and Southeast Asia have the highest incidence of HCC in the world^[3]. However, the management of patients with HCC has yet to be standardized in aspects of diagnosis, staging and treatment. Although the management of HCC in the West is mainly based on the Barcelona Clinic for Liver Cancer (BCLC) staging^[4], it is considered too conservative by Asian countries. With advancement in diagnosis, staging and treatment, management algorithm of HCC is further modified. The aim of the present review is to provide a summary and update for clinical practice to determine the most appropriate treatment for HCC patients.

DIAGNOSIS

With clinical suspicion or screening, the diagnosis of HCC is based on laboratory tests, radiological imaging and, where appropriate, liver biopsy. The American Association for the Study of Liver Disease (AASLD)^[5] diagnostic algorithm is widely used for surveillance and diagnosis. In short, nodules less than 1 cm which cannot be precisely characterised in ultrasound are subjected to interval scan. Nodules detected at ultrasound with diameter greater than 10 mm are further investigated with contrast computed tomography (CT) or magnetic resonance imaging (MRI). Nodules with typical feature of arterial enhancement and porto-venous washout are treated as HCC^[6].

MRI was reported to have a higher sensitivity compared with CT^[7]. In cases in which the diagnosis is uncertain, a serum alpha-fetoprotein (AFP) level > 400 ng/mL has a high positive predictive value^[8]. The sensitivity of MRI scan with contrast ranged from 33% to 61.7% according to different studies targeted for lesions smaller than 2 cm^[9]. In order to provide better results, the use of gadoxetic acid-enhanced MRI as an investigation tool has been widely investigated. The initial result of Primovist base MRI showed an improved sensitivity from 64% to 86%^[10].

Dual tracer positron emission tomography (PET)-CT with ¹¹C-acetate and ¹⁸F-fludeoxyglucose (FDG) markers was reported to have high sensitivity and specificity for diagnosis of HCC. The liver helps to maintain glucose homeostasis^[11] and there are a variety of different levels of glucose-6-phosphatase activity and glucose transporters in HCC^[12-14]. It was reported that well-differentiated HCCs preferentially accumulate ¹¹C-acetate^[15] and poorly differentiated tumours tend to preferentially accumulate FDG. Ho *et al.*^[15] found dual-tracer PET-CT to have a sensitivity of 98% and a specificity of 86% which were considered significantly improved to other imaging modality alone^[16]. Apart from higher sensitivity, the ¹⁸F-FDG tracer played an additional

role in providing prognostic indicators to lesion with poorly differentiated HCCs^[17].

Tumour biopsy can be done if non-invasive studies failed to characterize the lesion.

Diagnostic strategies vary between guidelines, *e.g.*, European Association for the Study of the Liver^[18] and AASLD^[19], but the process is generally determined by the size of liver nodules. The recently developed technique of dual-tracer PET-CT may help for atypical lesions.

Knowing that in around 30% patients with HCC, the AFP level remains normal, a high index of suspicion is crucial particularly in area like Southeast Asia where hepatitis B is endemic.

STAGING

Cancer staging is the process of determining the extent to which a cancer has developed and help to select the most appropriate treatment for any particular stage of disease^[20]. The prognosis and treatment outcome of HCC is related with tumour staging, liver function and patient's physical status^[19]. The BCLC staging system^[21] and the newly developed Hong Kong Liver Cancer (HKLC) staging system^[22] addresses all these factors. A number of other staging systems for HCC are available, *e.g.*, TNM system^[23], The Cancer of Liver Italian Program^[24], Okuda staging system^[25], *etc.*, but they only included some of these related factors.

In Eastern Asia where the highest incidence rates (> 20/100000 per year) of HCC occur, hepatitis B infection accounts for 70% of HCC cases^[26]. While in Europe and North America where lower incidence rates (< 5/100000 per year) of HCC, hepatitis C and alcohol are the major etiologies. In view of the difference in epidemiologic and clinical characteristics, different therapeutic approaches were developed in the East and West centres^[4,22,27,28]. Indeed, until recently, studies comparing treatment outcomes of eastern and western experiences with HCC are lacking.

The BCLC is widely used and quoted in the literature. However, it was derived from analysis of cohorts involving mainly Caucasian and may work better in Caucasian populations^[29-31]. In Asia, more aggressive treatment options were recommended especially for BCLC intermediate- and advanced-stage patients^[32,33]. The differences of treatment algorithms of APASL guideline, Japan Society of Hepatology guidelines, HKLC and BCLC staging systems were summarized in Table 1. These guidelines are followed by the corresponding community. However, the comparison between treatment outcomes following different algorithms is subjected to future study.

Recently, a new HCC classification system has been proposed in Hong Kong in order to provide a better guideline in area where the proportion of HCC and cirrhosis is higher. Although BCLC staging had fairly good discriminatory power in the test set, HKLC staging was significantly better than BCLC staging statistically in stratifying HCC patients into different prognostic groups. Overall, our HKLC treatment algorithm yielded

Table 1 Comparison between treatment algorithms of Asian guidelines for hepatocellular carcinoma and Barcelona Clinic for Liver Cancer staging system

	The HKLC staging system ^[22]	The JSH guidelines ^[28]	The APASL guidelines ^[27]	The BCLC staging system ^[4]
Parameters included	Performance status Liver function Vascular invasion/metastases Tumour staging	Liver function Vascular invasion/metastases Tumour staging	Liver function Vascular invasion/metastases Tumour staging	Performance status Liver function Vascular invasion/metastases Tumour staging
Definition of vascular invasion	Extrahepatic vascular invasion: main portal vein and inferior vena cava invasion	Portal vein invasion categorized into Vp1-4	Invasion to hepatic/portal vein branches	Portal vein invasion considered as advanced stage
Definition of tumour staging	3 categories: early, intermediate, locally advanced	Categories according to number and size	3 categories: resectable, non-resectable within Milan criteria, non-resectable exceeding Milan criteria	5 categories: very early, early, intermediate, advanced and terminal stages
Criteria for resection	Early tumour, Child A/B and intermediate tumour Child A Left or right portal vein invasion can be considered for resection	Any resectable HCC	Resection can be considered for number ≥ 4 although TACE is the first choice HCC with portal invasion at second or more peripheral portal branch can be considered for resection	Only solitary HCC or 3 nodules < 3 cm are subjected to resection

HKLC: Hong Kong Liver Cancer; JSH: Japan Society of Hepatology; BCLC: Barcelona Clinic for Liver Cancer; HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization; APASL: The Asian Pacific Association for the Study of the Liver.

better survival outcomes when compared with the BCLC treatment algorithm, as evidenced by the hypothetical survival curves. The effectiveness of the HKLC treatment guidelines vs the BCLC treatment schedule has been clearly observed in the aforementioned patient subsets. The Hong Kong group showed better survival outcomes can be achieved if these patients received a more radical approach of therapies^[22].

LIVER RESECTION

Pre-operative patient evaluation and case selection

Liver resection follows the basic principle of surgery. The patients have to be fully assessed for performance status and anaesthesiology fitness together with the tumour status including the tumour locations. Although BCLC criteria do not suggest liver resection for Stage B disease which comprise of tumour larger than 5 cm in size, many centres in Asia does not consider tumour size as an absolute contraindication to surgery. In many of the Asian centres including Hong Kong will consider hepatectomy for HCC as long as there is no extrahepatic disease or multifocal diffuse disease^[34].

The other factor that affects liver resection is liver function reserve assessment. More than 80% of patients with HCC are hepatitis B carrier and around half of these patients have different degree of cirrhosis. It is important that patients with poor liver function reserve should not receive excessive removal of liver parenchyma in order to avoid postoperative liver failure. In general only selected patients with Child A cirrhosis should be considered for major hepatectomy^[35]. In addition, several adjuvant investigations are crucial as part of preoperative liver function assessment.

Indocyanine green clearance test: Indocyanine green (ICG) is a dye which binds completely to albumin and β -lipoprotein and is exclusively removed by the liver and excreted unchanged in bile without any entero-hepatic circulation^[36]. The ICG retention at 15 min (ICGR-15) can be measured with serial blood sampling or pulse spectrophotometry methods^[37,38]. ICGR-15 is about 10% in normal person. It was shown to be correlated with hospital mortality so that it was recommended that ICGR-15 for a safe major and minor hepatectomy are 14% and 22%, respectively^[35].

Imaging-based volumetry: Liver volumetry is most commonly estimated with 3-D volume CT calculation^[39]. The post-operative residual liver volume [future liver remnant (FLR)] can be calculated based on cross-imaging techniques, on each slice FLR are outlined and integrated^[40]. The estimated standard liver volume (ESLV) can be calculated with a formula based upon regression analysis of normal population in which body weight and height are included^[41,42]. The FLR-to-ESLV ratio was shown to have inverse correlation with increasing risk for post-hepatectomy liver failure and post-operative death.

The critical residual liver volume for patients with normal liver had been reported to be 20%-30% according to different authors^[43-47]. In general FLR > 20% is considered safe and with low risk of postoperative hepatic dysfunction^[46]. However, most HCCs are associated with cirrhotic liver or diseased liver. The safety of surgical resection is greatly determined by the degree of liver dysfunction due to the underlying liver disease^[48,49]. In literature, it is generally accepted that the FLR required is considerably larger than those with a normal liver, given the impaired baseline function of hepatocytes. It was

reported that FLR > 30%-50% are considered safe for patients with diseased liver^[50-52].

SURGICAL RESECTION

The aim of hepatectomy is to obtain radical resection with adequate liver reserve. When performed in specialised centres, hepatectomy can achieve 5-year survival above 50%^[53]. In the more aggressive APASL guideline, the only contraindication to resection is the presence of distant metastases, main portal vein or inferior vena cava involvement^[27]. Even for advanced tumour > 5 cm or multinodular (> 3 nodules), a 5-year survival of 39% was reported^[34] comparing with 5-year survival for transarterial chemoembolisation (TACE) was only 6%-19%^[54-56]. While following the BCLC protocol, patients with multinodular tumours would be excluded for surgical resection. Vascular invasion was associated with poor prognosis in untreated patients^[4]. As liver transplant is contraindicated and TACE or systemic therapy is ineffective, surgical resection remains the only possible curative treatment in patients with good liver reserve. Five years survival of patients with portal vein thrombus underwent liver resection was reported to be 26%-42%^[57,58].

Conventionally, liver resection is mainly carried by open approach. In recent years, laparoscopic liver resection for cancer has gaining popularity and many results showed that minimally invasive approach can produce equally good oncological outcome even in patients with liver cirrhosis for minor hepatectomy^[59].

Laparoscopic hepatectomy was initially adopted to treat peripheral, benign tumour in a normal liver. Multiple series showed the feasibility of its application for HCC^[60]. However, patient selection needs to be careful. Some technical manoeuvres frequently used in open hepatectomy, such as organ mobilization, control of vascular inflow, and hanging manoeuvre are difficult in laparoscopic setting and controlling haemorrhage is also difficult. The Louisville consensus suggested that the laparoscopic approach to left lateral sectionectomy should be considered standard practice^[61].

PORTAL VEIN EMBOLISATION AND THE ASSOCIATING LIVER PARTITION WITH PORTAL VEIN LIGATION FOR STAGED HEPATECTOMY

Hepatectomy is the only option for long term survival for many patients with HCC. However, the resectability rate for HCC is approximately 20%-30% with normal liver, and further reduced in patients with cirrhotic liver^[62]. Portal vein embolisation (PVE) is one of the methods to stimulate growth of the FLR. Kinoshita *et al.*^[63] reported the first preoperative PVE in 1986. Various techniques for PVE were reported and percutaneous transhepatic technique has become the standard technique for PVE.

The mean period between PVE and hepatectomy was reported to be 37 d (range: 21-84 d) and the mean hypertrophy rate of FLR was reported to be 38%^[64]. On the other hand, approximately 10% of patient cannot have the surgery performed because of failure of PVE, inadequate hypertrophy, complication leading to unresectability and local tumour progression^[64].

The associating liver partition with portal vein ligation for staged hepatectomy approach associates in-situ splitting to portal vein ligation. It has been shown to be effective for the induction of rapid FLR hypertrophy so as to improve the resectability^[65]. It was proposed that the portal flow deprivation in future resected liver and accentuated inflammatory response induces faster regeneration compared to traditional portal vein occlusion methods^[66]. Therefore, the approach may reduce dropout in patients with marginally resectable disease but the midterm and long-term results are still to be confirmed.

LOCAL ABLATION THERAPY

Local ablation therapy is used in patients with early-stage HCC who are not suitable for surgical resection^[67]. The currently preferred methods included radiofrequency ablation, microwave ablation and High Intensity Focused Ultrasound (HIFU).

Radiofrequency ablation (RFA) utilises alternating electrical current with a frequency 200 k-20 MHz in the range of radio-waves and causes coagulative necrosis and tissue desiccation^[68]. RFA has largely replaced percutaneous ethanol injection because it produces better recurrence-free survival and requires fewer treatment sessions^[69]. RFA can be performed percutaneously under image guidance or during surgery guided by intraoperative ultrasound. Complete ablation of small lesions is possible in more than 90% of cases^[70]. The overall 5-year survival rates between 33% and 55% in selected series^[71], and lower mortality and morbidity rates were reported^[72]. Therefore, RFA is considered as an alternative to resection especially for small HCC. Three randomized controlled trials are available comparing hepatic resection and RFA^[73-75]. Although they reported conflicting results, it seems reasonable to offer RFA to very small HCC (< 2 cm) with no technical contraindications^[76]. Except for the use of RFA on solitary tumours, multifocal tumour prevalence was also high in ablated patients. Rather than competing techniques, RFA can sometimes be combined with hepatectomy tailored to suit the anatomical condition.

Microwave ablation (MWA) utilizes electromagnetic methods for tumour destruction with frequency \geq 900 MHz^[77]. Microwave ablation can achieve higher temperature^[78] shorter ablation time^[78-81] and does not require the placement of ground pads. Several studies^[82-84] showed that the local tumour control, complications and long-term survival were equivalent for RFA and MWA in the treatment of HCC.

HIFU is a non-invasive modality that uses an

extracorporeal source of focused ultrasound energy^[85]. It is able to induce coagulative necrosis in selected tissues. HIFU ablation utilizes a unique frequency of ultrasound wave of 0.8 to 3.5 MHz, which can be focused at a distance from the therapeutic transducer. The accumulated energy at the focused region induces necrosis of the target lesion by elevating the tissue temperature to above 60 °C. Temperature outside the focus point remains static as particle oscillation remains minimal. As ultrasound energy travels much better in water than in air, the presence of ascites in HCC patients actually facilitates energy propagation to the target HCC. Passage of energy without the puncture of a physical instrument and its superior performance in patients with ascites give HIFU ablation superiority over other treatment modalities for HCC. Initial results of HIFU ablation in the management of HCC were promising with a complete ablation rate of 28.5% to 68% for single treatment^[86]. This non-invasive approaches has shown to produce very little collateral damage to the normal liver parenchymal in patients with cirrhosis and is well tolerated even in selected patients with Child Pugh C liver cirrhosis. HIFU was also shown to be safe and effective to reduce the drop-out rate of liver transplant candidate^[87].

LIVER TRANSPLANTATION

Liver transplantation treats HCC together with the underlying liver disease. The Milan criteria (single tumour ≤ 5 cm, up to 3 tumours each ≤ 3 cm in diameter) is the gold standard for selection of deceased donor liver transplantation (DDLT). The disease-free survival at 4 years for patients within the criteria was reported to be 92%^[88]. Many centres extended the criteria as evidence showed that patients outside the Milan criteria also have favourable outcomes after liver transplantation. In the west, the University of California, San Francisco criteria (single tumour ≤ 6.5 cm, up to 3 tumours at most with the largest ≤ 4.5 cm, and total diameter ≤ 8 cm) had been shown with comparable outcome with Milan criteria^[89]. Asian centres extended the HCC transplant criteria further because the majority of liver grafts were from living donor^[90-93]. Living donor organ is considered a "gift" and there is less societal concern of equity^[94].

In Asia, the organ donation rates remain the lowest worldwide^[90]. As a result, living donor liver transplantation (LDLT) comprises the major workload and becomes an important treatment option for managing HCC in Asia. The overall survival rates were shown to be the same with studies comparing outcomes of DDLT and LDLT^[95-99].

In view of the shortage of donated organ in Asia, multiple strategies had been developed, including using marginal livers, domino donors, and split liver transplant. Also bridging therapy with ablative and transarterial interventions aims to prevent tumour progression^[100]. However, in survey up to 2005, 96% of liver transplant for HCC in Asian centers were from live donors^[90].

TRANSARTERIAL LOCOREGIONAL THERAPY

TACE is the most widely used treatment for HCCs which are unresectable or cannot be effectively treated with percutaneous intervention for over 3 decades^[54,101,102]. During the procedure, iodized poppy seed oil (lipiodol) and chemotherapeutic agents are administered through the feeding artery of the tumour, followed by arterial embolization. TACE results in delay tumour progression and vascular invasion and result in a survival benefit compared with conservative management. The most important aspect is the selection of patients, *i.e.*, patients should have preserved liver function, with no portal vein thrombosis and extrahepatic spread. A meta-analysis of six trials found a survival benefit for TACE over conservative management^[101]. Two-year survival rates were reported as 31% vs 11% for conservative treatment^[54]. TACE can be combined with other ablative therapies such as RFA^[103,104].

The use of drug eluting bead (DEB) in TACE was reported in 2007^[105,106] for its safety and efficacy. Microspheres composed of synthetic polymers or natural materials such as albumin, gelatine, chitosa or aliginate roughly fall into two categories - 15-60 μm and 100-250 μm ^[107]. Drugs included doxorubicin, mitomycin C, cisplatin, *etc.*, can be loaded to the beads^[107]. DEBs have potential to simplify and standardize the TACE procedure by preloading the embolic with drug followed by controlled drug elution in target tissue^[107]. A randomized controlled trial in 212 patients with HCC demonstrated that DEB-TACE is better tolerated than conventional lipiodol-based TACE, but this trial failed to demonstrate superiority in tumour response^[108].

Transarterial radioembolization (TARE) using yttrium-90 microspheres can be used for patients with portal vein thrombosis^[109-115]. Tumoricidal radiation doses are delivered with minimal toxicity to functional liver and there is minimal to moderate embolization (micro-embolization) and minimal alteration in vascularity with TARE. Several authors have compared outcomes following TACE with TARE in matched patient cohorts, and reported comparable efficacy for TACE and TARE in terms of tumour response and overall survival^[116-119]. However, randomized controlled trials comparing their efficacy with other therapies are lacking^[120].

SYSTEMIC THERAPY

Systemic chemotherapy had a disappointing record in management of HCC^[121]. With recent knowledge of hepato-carcinogenesis, there has been encouraging development in target therapy of advanced HCC. Sorafenib is an oral multikinase inhibitor that has activity against several serine/threonine kinases and tyrosine kinases. It was the first systemic therapy shown to prolong survival in patients with HCC, and is approved for use in advanced HCC^[122]. The Sorafenib HCC Assessment Randomized

Protocol trial^[123] is a large, placebo-controlled phase III trial in patients with advanced HCC and preserved liver function (Child-Pugh class A). It demonstrated prolonged median survival for approximately 3 mo in sorafenib group. Cheng *et al.*^[124] in another study involving 271 Asian patients showed a 2 mo prolongation in survival in patients with advanced HCC. Many other novo agents were being investigated at the moment but it was only Sorafenib that has demonstrated the effect of providing significant longer overall survival.

CONCLUSION

Management of HCC has changed significantly over the past several decades. However, the management of patients has yet to be standardized. As a result of high prevalence of hepatitis B infection in Asia, the experience of the East helped to develop a more aggressive management algorithm. To ensure the most effective treatment to be offered for HCC patients, a good patient selection for the right modality need to be practised.

REFERENCES

- 1 **Ferlay J**, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010; **127**: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]
- 2 **Poon D**, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, Khin MW, Koo WH. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. *Lancet Oncol* 2009; **10**: 1111-1118 [PMID: 19880065 DOI: 10.1016/S1470-2045(09)70241-4]
- 3 **Ferlay J**, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; **136**: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]
- 4 **Llovet JM**, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. *Semin Liver Dis* 1999; **19**: 329-338 [PMID: 10518312 DOI: 10.1055/s-2007-1007122]
- 5 **Bruix J**, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology* 2011; **53**: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]
- 6 **Sangiovanni A**, Manini MA, Iavarone M, Romeo R, Forzenigo LV, Fraquelli M, Massironi S, Della Corte C, Ronchi G, Rumi MG, Biondetti P, Colombo M. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. *Gut* 2010; **59**: 638-644 [PMID: 19951909 DOI: 10.1136/gut.2009.187286]
- 7 **Davis GL**, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK, Goldstein RM. Hepatocellular carcinoma: management of an increasingly common problem. *Proc (Bayl Univ Med Cent)* 2008; **21**: 266-280 [PMID: 18628926]
- 8 **El-Serag HB**. Hepatocellular carcinoma. *N Engl J Med* 2011; **365**: 1118-1127 [PMID: 21992124 DOI: 10.1056/NEJMra1001683]
- 9 **Digumarthy SR**, Sahani DV, Saini S. MRI in detection of hepatocellular carcinoma (HCC). *Cancer Imaging* 2005; **5**: 20-24 [PMID: 16154814 DOI: 10.1102/1470-7330.2005.0005]
- 10 **Park G**, Kim YK, Kim CS, Yu HC, Hwang SB. Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine. *Br J Radiol* 2010; **83**: 1010-1016 [PMID: 20682591 DOI: 10.1259/bjr/66686028]
- 11 **Raddatz D**, Ramadori G. Carbohydrate metabolism and the liver: actual aspects from physiology and disease. *Z Gastroenterol* 2007; **45**: 51-62 [PMID: 17236121 DOI: 10.1055/s-2006-927394]
- 12 **Torizuka T**, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, Tanaka A, Yamaoka Y, Yamamoto K, Konishi J. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. *J Nucl Med* 1995; **36**: 1811-1817 [PMID: 7562048]
- 13 **Salem N**, MacLennan GT, Kuang Y, Anderson PW, Schomisch SJ, Tochkov IA, Tennant BC, Lee Z. Quantitative evaluation of 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography imaging on the woodchuck model of hepatocellular carcinoma with histological correlation. *Mol Imaging Biol* 2007; **9**: 135-143 [PMID: 17308952 DOI: 10.1007/s11307-007-0092-5]
- 14 **Lee JD**, Yang WI, Park YN, Kim KS, Choi JS, Yun M, Ko D, Kim TS, Cho AE, Kim HM, Han KH, Im SS, Ahn YH, Choi CW, Park JH. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake. *J Nucl Med* 2005; **46**: 1753-1759 [PMID: 16204727]
- 15 **Ho CL**, Chen S, Yeung DW, Cheng TK. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. *J Nucl Med* 2007; **48**: 902-909 [PMID: 17504862 DOI: 10.2967/jnumed.106.036673]
- 16 **Cheung TT**, Ho CL, Lo CM, Chen S, Chan SC, Chok KS, Fung JY, Yan Chan AC, Sharr W, Yau T, Poon RT, Fan ST. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspective. *J Nucl Med* 2013; **54**: 192-200 [PMID: 23321459 DOI: 10.2967/jnumed.112.107516]
- 17 **Cheung TT**, Chan SC, Ho CL, Chok KS, Chan AC, Sharr WW, Ng KK, Poon RT, Lo CM, Fan ST. Can positron emission tomography with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma? *Liver Transpl* 2011; **17**: 1218-1225 [PMID: 21688383 DOI: 10.1002/lt.22362]
- 18 **Bruix J**, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. *J Hepatol* 2001; **35**: 421-430 [PMID: 11592607]
- 19 **Bruix J**, Sherman M. Management of hepatocellular carcinoma. *Hepatology* 2005; **42**: 1208-1236 [PMID: 16250051 DOI: 10.1002/hep.20933]
- 20 **Pons F**, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. *HPB (Oxford)* 2005; **7**: 35-41 [PMID: 18333159 DOI: 10.1080/13651820410024058]
- 21 **Llovet JM**, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ. Design and endpoints of clinical trials in hepatocellular carcinoma. *J Natl Cancer Inst* 2008; **100**: 698-711 [PMID: 18477802 DOI: 10.1093/jnci/djn134]
- 22 **Yau T**, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. *Gastroenterology* 2014; **146**: 1691-1700.e3 [PMID: 24583061 DOI: 10.1053/j.gastro.2014.02.032]
- 23 **American Joint Committee on Cancer**. AJCC Cancer Staging Manual (6th Edition). NY, USA: Springer-Verlag, 2002
- 24 A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. *Hepatology* 1998; **28**: 751-755 [PMID: 9731568 DOI: 10.1002/hep.510280322]
- 25 **Okuda K**, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. *Cancer* 1985; **56**: 918-928 [PMID: 2990661]
- 26 **Jia JD**, Zhuang H. A winning war against hepatitis B virus infection in China. *Chin Med J (Engl)* 2007; **120**: 2157-2158 [PMID: 18167195]
- 27 **Omata M**, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL,

- Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. *Hepatol Int* 2010; **4**: 439-474 [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7]
- 28 **Kudo M**, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. *Dig Dis* 2011; **29**: 339-364 [PMID: 21829027 DOI: 10.1159/000327577]
- 29 **Cillo U**, Bassanello M, Vitale A, Grigoletto FA, Burra P, Fagioli S, D'Amico F, Ciarleglio FA, Boccagni P, Brolese A, Zanus G, D'Amico DF. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? *J Hepatol* 2004; **40**: 124-131 [PMID: 14672623]
- 30 **Grieco A**, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, Rapaccini GL, Gasbarrini G. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. *Gut* 2005; **54**: 411-418 [PMID: 15710992 DOI: 10.1136/gut.2004.048124]
- 31 **Marrero JA**, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. *Hepatology* 2005; **41**: 707-716 [PMID: 15795889 DOI: 10.1002/hep.20636]
- 32 **Wang JH**, Changchien CS, Hu TH, Lee CM, Kee KM, Lin CY, Chen CL, Chen TY, Huang YJ, Lu SN. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. *Eur J Cancer* 2008; **44**: 1000-1006 [PMID: 18337087 DOI: 10.1016/j.ejca.2008.02.018]
- 33 **Vitale A**, Saracino E, Boccagni P, Brolese A, D'Amico F, Gringeri E, Neri D, Srsen N, Valmasoni M, Zanus G, Carraro A, Violi P, Pauletto A, Bassi D, Polacco M, Burra P, Farinati F, Feltracco P, Romano A, D'Amico DF, Cillo U. Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. *Transplant Proc* 2009; **41**: 1260-1263 [PMID: 19460533 DOI: 10.1016/j.transproceed.2009.03.054]
- 34 **Ng KK**, Vauthey JN, Pawlik TM, Lauwers GY, Regimbeau JM, Belghiti J, Ikai I, Yamaoka Y, Curley SA, Nagorney DM, Ng IO, Fan ST, Poon RT. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. *Ann Surg Oncol* 2005; **12**: 364-373 [PMID: 15915370 DOI: 10.1245/ASO.2005.06.004]
- 35 **Fan ST**. Liver functional reserve estimation: state of the art and relevance for local treatments: the Eastern perspective. *J Hepatobiliary Pancreat Sci* 2010; **17**: 380-384 [PMID: 19865790 DOI: 10.1007/s00534-009-0229-9]
- 36 **Caesar J**, Shaldon S, Chiandussi L, Guevara L, Sherlock S. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. *Clin Sci* 1961; **21**: 43-57 [PMID: 13689739]
- 37 **Purcell R**, Kruger P, Jones M. Indocyanine green elimination: a comparison of the LiMON and serial blood sampling methods. *ANZ J Surg* 2006; **76**: 75-77 [PMID: 16483302 DOI: 10.1111/j.1445-2197.2006.03643.x]
- 38 **de Liguori Carino N**, O'Reilly DA, Dajani K, Ghaneh P, Poston GJ, Wu AV. Perioperative use of the LiMON method of indocyanine green elimination measurement for the prediction and early detection of post-hepatectomy liver failure. *Eur J Surg Oncol* 2009; **35**: 957-962 [PMID: 19250796 DOI: 10.1016/j.ejso.2009.02.003]
- 39 **Heymtsfield SB**, Fulenwider T, Nordlinger B, Barlow R, Sones P, Kutner M. Accurate measurement of liver, kidney, and spleen volume and mass by computerized axial tomography. *Ann Intern Med* 1979; **90**: 185-187 [PMID: 443650]
- 40 **Kawasaki S**, Makuuchi M, Matsunami H, Hashikura Y, Ikegami T, Chisuiwa H, Ikeno T, Noike T, Takayama T, Kawarazaki H. Preoperative measurement of segmental liver volume of donors for living related liver transplantation. *Hepatology* 1993; **18**: 1115-1120 [PMID: 8225216]
- 41 **Urata K**, Kawasaki S, Matsunami H, Hashikura Y, Ikegami T, Ishizone S, Momose Y, Komiyama A, Makuuchi M. Calculation of child and adult standard liver volume for liver transplantation. *Hepatology* 1995; **21**: 1317-1321 [PMID: 7737637]
- 42 **Chan SC**, Lo CM, Chok KS, Sharr WW, Cheung TT, Tsang SH, Chan AC, Fan ST. Validation of graft and standard liver size predictions in right liver living donor liver transplantation. *Hepatol Int* 2011; **5**: 913-917 [PMID: 21484120 DOI: 10.1007/s12072-011-9264-0]
- 43 **Abdalla EK**, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. *Arch Surg* 2002; **137**: 675-680; discussion 680-681 [PMID: 12049538]
- 44 **Shoup M**, Gonen M, D'Angelica M, Jarnagin WR, DeMatteo RP, Schwartz LH, Tuorto S, Blumgart LH, Fong Y. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. *J Gastrointest Surg* 2003; **7**: 325-330 [PMID: 12654556]
- 45 **Vauthey JN**, Chaoui A, Do KA, Bilimoria MM, Fenstermacher MJ, Charnsangavej C, Hicks M, Alsfasser G, Lauwers G, Hawkins IF, Caridi J. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. *Surgery* 2000; **127**: 512-519 [PMID: 10819059 DOI: 10.1067/msy.2000.105294]
- 46 **Abdalla EK**, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. *Ann Surg Oncol* 2006; **13**: 1271-1280 [PMID: 16955381 DOI: 10.1245/s10434-006-9045-5]
- 47 **Kishi Y**, Abdalla EK, Chun YS, Zorzi D, Madoff DC, Wallace MJ, Curley SA, Vauthey JN. Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. *Ann Surg* 2009; **250**: 540-548 [PMID: 19730239 DOI: 10.1097/SLA.0b013e3181b674df]
- 48 **Kubota K**, Makuuchi M, Kusaka K, Kobayashi T, Miki K, Hasegawa K, Harihara Y, Takayama T. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. *Hepatology* 1997; **26**: 1176-1181 [PMID: 9362359 DOI: 10.1053/jhep.1997.v26.pm0009362359]
- 49 **Shirabe K**, Shimada M, Gion T, Hasegawa H, Takenaka K, Utsunomiya T, Sugimachi K. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. *J Am Coll Surg* 1999; **188**: 304-309 [PMID: 10065820]
- 50 **van den Esschert JW**, de Graaf W, van Lienden KP, Busch OR, Heger M, van Delden OM, Gouma DJ, Bennink RJ, Laméris JS, van Gulik TM. Volumetric and functional recovery of the remnant liver after major liver resection with prior portal vein embolization: recovery after PVE and liver resection. *J Gastrointest Surg* 2009; **13**: 1464-1469 [PMID: 19475462 DOI: 10.1007/s11605-009-0929-0]
- 51 **Ferrero A**, Viganò L, Polastri R, Muratore A, Eminefendic H, Regge D, Capussotti L. Postoperative liver dysfunction and future remnant liver: where is the limit? Results of a prospective study. *World J Surg* 2007; **31**: 1643-1651 [PMID: 17551779 DOI: 10.1007/s00268-007-9123-2]
- 52 **Guglielmi A**, Ruzzenente A, Conci S, Valdegamberi A, Iacono C. How much remnant is enough in liver resection? *Dig Surg* 2012; **29**: 6-17 [PMID: 22441614 DOI: 10.1159/000335713]
- 53 **Lim KC**, Chow PK, Allen JC, Siddiqui FJ, Chan ES, Tan SB. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. *Br J Surg* 2012; **99**: 1622-1629 [PMID: 23023956 DOI: 10.1002/bjs.8915]
- 54 **Lo CM**, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology* 2002; **35**: 1164-1171 [PMID: 11981766 DOI: 10.1053/jhep.2002.33156]
- 55 **Ono Y**, Yoshimasu T, Ashikaga R, Inoue M, Shindou H, Fuji K, Araki Y, Nishimura Y. Long-term results of lipiodol-transcatheter

- arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. *Am J Clin Oncol* 2000; **23**: 564-568 [PMID: 11202797]
- 56 **O'Suilleabhain CB**, Poon RT, Yong JL, Ooi GC, Tso WK, Fan ST. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. *Br J Surg* 2003; **90**: 325-331 [PMID: 12594668 DOI: 10.1002/bjs.4045]
- 57 **Wu CC**, Hsieh SR, Chen JT, Ho WL, Lin MC, Yeh DC, Liu TJ, P'eng FK. An appraisal of liver and portal vein resection for hepatocellular carcinoma with tumor thrombi extending to portal bifurcation. *Arch Surg* 2000; **135**: 1273-1279 [PMID: 11074879]
- 58 **Minagawa M**, Makuuchi M, Takayama T, Ohtomo K. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. *Ann Surg* 2001; **233**: 379-384 [PMID: 11224626]
- 59 **Cheung TT**, Poon RT, Yuen WK, Chok KS, Jenkins CR, Chan SC, Fan ST, Lo CM. Long-term survival analysis of pure laparoscopic versus open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a single-center experience. *Ann Surg* 2013; **257**: 506-511 [PMID: 23299521 DOI: 10.1097/SLA.0b013e31827b947a]
- 60 **Chung CD**, Lau LL, Ko KL, Wong AC, Wong S, Chan AC, Poon RT, Lo CM, Fan ST. Laparoscopic liver resection for hepatocellular carcinoma. *Asian J Surg* 2010; **33**: 168-172 [PMID: 21377102 DOI: 10.1016/S1015-9584(11)60002-X]
- 61 **Buell JF**, Cherqui D, Geller DA, O'Rourke N, Iannitti D, Dagher I, Koffron AJ, Thomas M, Gayet B, Han HS, Wakabayashi G, Belli G, Kaneko H, Ker CG, Scatton O, Laurent A, Abdalla EK, Chaudhury P, Dutson E, Gamblin C, D'Angelica M, Nagorney D, Testa G, Labow D, Manas D, Poon RT, Nelson H, Martin R, Clary B, Pinson WC, Martinie J, Vauthey JN, Goldstein R, Roayaie S, Barlet D, Espat J, Abecassis M, Rees M, Fong Y, McMasters KM, Broelsch C, Busuttil R, Belghiti J, Strasberg S, Chari RS. The international position on laparoscopic liver surgery: The Louisville Statement, 2008. *Ann Surg* 2009; **250**: 825-830 [PMID: 19916210]
- 62 **Garcea G**, Ong SL, Maddern GJ. Predicting liver failure following major hepatectomy. *Dig Liver Dis* 2009; **41**: 798-806 [PMID: 19303376 DOI: 10.1016/j.dld.2009.01.015]
- 63 **Kinoshita H**. [Role of the scintigram in the diagnosis of thyroid diseases]. *Rinsho Hoshasen* 1986; **31**: 469-472 [PMID: 3735706]
- 64 **van Lienden KP**, van den Esschert JW, de Graaf W, Bipat S, Lameris JS, van Gulik TM, van Delden OM. Portal vein embolization before liver resection: a systematic review. *Cardiovasc Intervent Radiol* 2013; **36**: 25-34 [PMID: 22806245 DOI: 10.1007/s00270-012-0440-y]
- 65 **Schnitzbauer AA**, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, Fichtner-Feigl S, Lorf T, Goralczyk A, Hörbelt R, Kroemer A, Loss M, Rümmele P, Scherer MN, Padberg W, Königsrainer A, Lang H, Obed A, Schlitt HJ. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. *Ann Surg* 2012; **255**: 405-414 [PMID: 22330038 DOI: 10.1097/SLA.0b013e31824856f5]
- 66 **Vennarecci G**, Laurenzi A, Santoro R, Colasanti M, Lepiane P, Ettorre GM. The ALPPS procedure: a surgical option for hepatocellular carcinoma with major vascular invasion. *World J Surg* 2014; **38**: 1498-1503 [PMID: 24146197 DOI: 10.1007/s00268-013-2296-y]
- 67 **Sandhu DS**, Tharayil VS, Lai JP, Roberts LR. Treatment options for hepatocellular carcinoma. *Expert Rev Gastroenterol Hepatol* 2008; **2**: 81-92 [PMID: 19072372 DOI: 10.1586/17474124.2.1.81]
- 68 **Strasberg SM**, Linehan D. Radiofrequency ablation of liver tumors. *Curr Probl Surg* 2003; **40**: 459-498 [PMID: 12865889 DOI: 10.1016/S0011-3840(03)00050-9]
- 69 **Brunello F**, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P, Sacchetto P, Gandini G, Rizzetto M. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. *Scand J Gastroenterol* 2008; **43**: 727-735 [PMID: 18569991 DOI: 10.1080/0036520701885481]
- 70 **Livraghi T**, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, Rossi S. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? *Hepatology* 2008; **47**: 82-89 [PMID: 18008357 DOI: 10.1002/hep.21933]
- 71 **Lencioni R**, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, Bartolozzi C. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. *Radiology* 2005; **234**: 961-967 [PMID: 15665226 DOI: 10.1148/radiol.2343040350]
- 72 **Cheung TT**, Ng KK, Poon RT, Fan ST. Tolerance of radiofrequency ablation by patients of hepatocellular carcinoma. *J Hepatobiliary Pancreat Surg* 2009; **16**: 655-660 [PMID: 19370304 DOI: 10.1007/s00534-009-0103-9]
- 73 **Chen MS**, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. *Ann Surg* 2006; **243**: 321-328 [PMID: 16495695 DOI: 10.1097/01.sla.0000201480.65519.b8]
- 74 **Huang J**, Yan L, Cheng Z, Wu H, Du L, Wang J, Xu Y, Zeng Y. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. *Ann Surg* 2010; **252**: 903-912 [PMID: 21107100 DOI: 10.1097/SLA.0b013e3181efc656]
- 75 **Feng K**, Yan J, Li X, Xia F, Ma K, Wang S, Bie P, Dong J. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. *J Hepatol* 2012; **57**: 794-802 [PMID: 22634125 DOI: 10.1016/j.jhep.2012.05.007]
- 76 **Cucchetti A**, Piscaglia F, Cescon M, Ercolani G, Pinna AD. Systematic review of surgical resection vs radiofrequency ablation for hepatocellular carcinoma. *World J Gastroenterol* 2013; **19**: 4106-4118 [PMID: 23864773 DOI: 10.3748/wjg.v19.i26.4106]
- 77 **Simon CJ**, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. *Radiographics* 2005; **25** Suppl 1: S69-S83 [PMID: 16227498 DOI: 10.1148/rg.25si055501]
- 78 **Yu J**, Li X, Xing L, Mu D, Fu Z, Sun X, Sun X, Yang G, Zhang B, Sun X, Ling CC. Comparison of tumor volumes as determined by pathologic examination and FDG-PET/CT images of non-small-cell lung cancer: a pilot study. *Int J Radiat Oncol Biol Phys* 2009; **75**: 1468-1474 [PMID: 19464822 DOI: 10.1016/j.ijrobp.2009.01.019]
- 79 **Li X**, Zhang L, Fan W, Zhao M, Wang L, Tang T, Jiang H, Zhang J, Liu Y. Comparison of microwave ablation and multipolar radiofrequency ablation, both using a pair of internally cooled interstitial applicators: results in ex vivo porcine livers. *Int J Hyperthermia* 2011; **27**: 240-248 [PMID: 21501025 DOI: 10.3109/02656736.2010.536967]
- 80 **Fan W**, Li X, Zhang L, Jiang H, Zhang J. Comparison of microwave ablation and multipolar radiofrequency ablation in vivo using two internally cooled probes. *AJR Am J Roentgenol* 2012; **198**: W46-W50 [PMID: 22194514 DOI: 10.2214/AJR.11.6707]
- 81 **Wright AS**, Sampson LA, Warner TF, Mahvi DM, Lee FT. Radiofrequency versus microwave ablation in a hepatic porcine model. *Radiology* 2005; **236**: 132-139 [PMID: 15987969 DOI: 10.1148/radiol.2361031249]
- 82 **Simo KA**, Sereika SE, Newton KN, Gerber DA. Laparoscopic-assisted microwave ablation for hepatocellular carcinoma: safety and efficacy in comparison with radiofrequency ablation. *J Surg Oncol* 2011; **104**: 822-829 [PMID: 21520094 DOI: 10.1002/jso.21933]
- 83 **Lu MD**, Xu HX, Xie XY, Yin XY, Chen JW, Kuang M, Xu ZF, Liu GJ, Zheng YL. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. *J Gastroenterol* 2005; **40**: 1054-1060 [PMID: 16322950 DOI: 10.1007/s00535-005-1671-3]
- 84 **Shibata T**, Iimuro Y, Yamamoto Y, Maetani Y, Ametani F, Itoh K, Konishi J. Small hepatocellular carcinoma: comparison of radiofrequency ablation and percutaneous microwave coagulation therapy. *Radiology* 2002; **223**: 331-337 [PMID: 11997534 DOI: 10.1148/radiol.2232010775]
- 85 **Lynn JG**, Zwemer RL, Chick AJ, Miller AE. A new method for the generation and use of focused ultrasound in experimental biology.

- J Gen Physiol* 1942; **26**: 179-193 [PMID: 19873337]
- 86 **Ng KK**, Poon RT, Chan SC, Chok KS, Cheung TT, Tung H, Chu F, Tso WK, Yu WC, Lo CM, Fan ST. High-intensity focused ultrasound for hepatocellular carcinoma: a single-center experience. *Ann Surg* 2011; **253**: 981-987 [PMID: 21394012 DOI: 10.1097/SLA.0b013e3182128a8b]
 - 87 **Cheung TT**, Fan ST, Chan SC, Chok KS, Chu FS, Jenkins CR, Lo RC, Fung JY, Chan AC, Sharr WW, Tsang SH, Dai WC, Poon RT, Lo CM. High-intensity focused ultrasound ablation: an effective bridging therapy for hepatocellular carcinoma patients. *World J Gastroenterol* 2013; **19**: 3083-3089 [PMID: 23716988 DOI: 10.3748/wjg.v19.i20.3083]
 - 88 **Mazzaferro V**, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996; **334**: 693-699 [PMID: 8594428 DOI: 10.1056/NEJM199603143341104]
 - 89 **Yao FY**, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. *Hepatology* 2001; **33**: 1394-1403 [PMID: 11391528 DOI: 10.1053/jhep.2001.24563]
 - 90 **de Villa V**, Lo CM. Liver transplantation for hepatocellular carcinoma in Asia. *Oncologist* 2007; **12**: 1321-1331 [PMID: 18055852 DOI: 10.1634/theoncologist.12-11-1321]
 - 91 **Ito T**, Takada Y, Ueda M, Haga H, Maetani Y, Oike F, Ogawa K, Sakamoto S, Ogura Y, Egawa H, Tanaka K, Uemoto S. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. *Liver Transpl* 2007; **13**: 1637-1644 [PMID: 18044766 DOI: 10.1002/lt.21281]
 - 92 **Lee SG**, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, Ko GY, Park KM, Ha TY, Song GW. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. *Liver Transpl* 2008; **14**: 935-945 [PMID: 18581465 DOI: 10.1002/lt.21445]
 - 93 **Tamura S**, Sugawara Y, Kokudo N. Living donor liver transplantation for hepatocellular carcinoma: the Japanese experience. *Oncology* 2011; **81** Suppl 1: 111-115 [PMID: 22212944 DOI: 10.1159/000333270]
 - 94 **Grant D**, Fisher RA, Abecassis M, McCaughan G, Wright L, Fan ST. Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation? *Liver Transpl* 2011; **17** Suppl 2: S133-S138 [PMID: 21634006 DOI: 10.1002/lt.22348]
 - 95 **Kulik L**, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. *Gastroenterology* 2004; **127**: S277-S282 [PMID: 15508095]
 - 96 **Hwang S**, Lee SG, Joh JW, Suh KS, Kim DG. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. *Liver Transpl* 2005; **11**: 1265-1272 [PMID: 16184545 DOI: 10.1002/lt.20549]
 - 97 **Lo CM**, Fan ST, Liu CL, Chan SC, Ng IO, Wong J. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. *Br J Surg* 2007; **94**: 78-86 [PMID: 17016793 DOI: 10.1002/bjs.5528]
 - 98 **Di Sandro S**, Slim AO, Giacomoni A, Lauterio A, Mangoni I, Aseni P, Pirotta V, Aldumour A, Mihaylov P, De Carlis L. Living donor liver transplantation for hepatocellular carcinoma: long-term results compared with deceased donor liver transplantation. *Transplant Proc* 2009; **41**: 1283-1285 [PMID: 19460539 DOI: 10.1016/j.transproceed.2009.03.022]
 - 99 **Vakili K**, Pomposelli JJ, Cheah YL, Akoad M, Lewis WD, Khettry U, Gordon F, Khwaja K, Jenkins R, Pomfret EA. Living donor liver transplantation for hepatocellular carcinoma: Increased recurrence but improved survival. *Liver Transpl* 2009; **15**: 1861-1866 [PMID: 19938113 DOI: 10.1002/lt.21940]
 - 100 **Graziadei IW**, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbar K, Jaschke W, Margreiter R, Vogel W. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. *Liver Transpl* 2003; **9**: 557-563 [PMID: 12783395 DOI: 10.1053/jlts.2003.50106]
 - 101 **Llovet JM**, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet* 2002; **359**: 1734-1739 [PMID: 12049862 DOI: 10.1016/S0140-6736(02)08649-X]
 - 102 **Llovet JM**, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. *Hepatology* 2003; **37**: 429-442 [PMID: 12540794 DOI: 10.1053/jhep.2003.50047]
 - 103 **Vogl TJ**, Naguib NN, Nour-Eldin NE, Rao P, Emami AH, Zangos S, Nabil M, Abdelkader A. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. *Eur J Radiol* 2009; **72**: 505-516 [PMID: 18835117 DOI: 10.1016/j.ejrad.2008.08.007]
 - 104 **Cheng BQ**, Jia CQ, Liu CT, Fan W, Wang QL, Zhang ZL, Yi CH. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. *JAMA* 2008; **299**: 1669-1677 [PMID: 18398079 DOI: 10.1001/jama.299.14.1669]
 - 105 **Poon RT**, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, Fan ST. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. *Clin Gastroenterol Hepatol* 2007; **5**: 1100-1108 [PMID: 17627902 DOI: 10.1016/j.cgh.2007.04.021]
 - 106 **Varela M**, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montaña X, Llovet JM, Bruix J. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. *J Hepatol* 2007; **46**: 474-481 [PMID: 17239480 DOI: 10.1016/j.jhep.2006.10.020]
 - 107 **Lewis AL**, Dreher MR. Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapy. *J Control Release* 2012; **161**: 338-350 [PMID: 22285550 DOI: 10.1016/j.jconrel.2012.01.018]
 - 108 **Lammer J**, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergeant G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. *Cardiovasc Intervent Radiol* 2010; **33**: 41-52 [PMID: 19908093 DOI: 10.1007/s00270-009-9711-7]
 - 109 **Salem R**, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. *Gastroenterology* 2010; **138**: 52-64 [PMID: 19766639 DOI: 10.1053/j.gastro.2009.09.006]
 - 110 **Hilgard P**, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, Heusner T, Cinnati VR, Paul A, Bockisch A, Gerken G, Antoch G. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. *Hepatology* 2010; **52**: 1741-1749 [PMID: 21038413 DOI: 10.1002/hep.23944]
 - 111 **Sangro B**, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Ettorre GM, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Inarrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Latorria S. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. *Hepatology* 2011; **54**: 868-878 [PMID: 21618574 DOI: 10.1002/hep.24451]
 - 112 **Inarrairaegui M**, Thurston KG, Bilbao JI, D'Avola D, Rodriguez M, Arbizu J, Martinez-Cuesta A, Sangro B. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. *J Vasc Interv Radiol* 2010; **21**: 1205-1212 [PMID: 20598574 DOI: 10.1016/

- j.jvir.2010.04.012]
- 113 **Tsai AL**, Burke CT, Kennedy AS, Moore DT, Mauro MA, Dixon RD, Stavas JM, Bernard SA, Khandani AH, O'Neil BH. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. *J Vasc Interv Radiol* 2010; **21**: 1377-1384 [PMID: 20691606 DOI: 10.1016/j.jvir.2010.04.027]
 - 114 **Woodall CE**, Scoggins CR, Ellis SF, Tatum CM, Hahl MJ, Ravindra KV, McMasters KM, Martin RC. Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? *J Am Coll Surg* 2009; **208**: 375-382 [PMID: 19317999 DOI: 10.1016/j.jamcollsurg.2008.12.009]
 - 115 **Kulik LM**, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, Sato KT, Benson A, Nemecek AA, Gates VL, Abecassis M, Omary RA, Salem R. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. *Hepatology* 2008; **47**: 71-81 [PMID: 18027884 DOI: 10.1002/hep.21980]
 - 116 **Lewandowski RJ**, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, Ibrahim SM, Sato KT, Baker T, Miller FH, Omary R, Abecassis M, Salem R. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. *Am J Transplant* 2009; **9**: 1920-1928 [PMID: 19552767 DOI: 10.1111/j.1600-6143.2009.02695.x]
 - 117 **Kooby DA**, Egnatashvili V, Srinivasan S, Chamsuddin A, Delman KA, Kauh J, Staley CA, Kim HS. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. *J Vasc Interv Radiol* 2010; **21**: 224-230 [PMID: 20022765 DOI: 10.1016/j.jvir.2009.10.013]
 - 118 **Carr BI**, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. *Cancer* 2010; **116**: 1305-1314 [PMID: 20066715 DOI: 10.1002/cncr.24884]
 - 119 **Salem R**, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemecek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB, Mulcahy MF. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. *Gastroenterology* 2011; **140**: 497-507.e2 [PMID: 21044630 DOI: 10.1053/j.gastro.2010.10.049]
 - 120 **Ibrahim SM**, Lewandowski RJ, Sato KT, Gates VL, Kulik L, Mulcahy MF, Ryu RK, Omary RA, Salem R. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. *World J Gastroenterol* 2008; **14**: 1664-1669 [PMID: 18350597]
 - 121 **Lai EC**, Choi TK, Cheng CH, Mok FP, Fan ST, Tan ES, Wong J. Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil. *Cancer* 1990; **66**: 1685-1687 [PMID: 2169994]
 - 122 **Llovet JM**, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. *Hepatology* 1999; **30**: 1434-1440 [PMID: 10573522 DOI: 10.1002/hep.510300629]
 - 123 **Llovet JM**, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; **359**: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
 - 124 **Cheng AL**, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2009; **10**: 25-34 [PMID: 19095497 DOI: 10.1016/S1470-2045(08)70285-7]

P- Reviewer: Morales-Gonzalez JA, Yeung CY **S- Editor:** Ma YJ
L- Editor: A **E- Editor:** Liu SQ





Published by **Baishideng Publishing Group Inc**

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>

